Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial

Direct‐acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection. Combining DAAs with different mechanisms may allow for shorter treatment durations that are effective across multiple genotypes. The aim of the C‐SWIFT study was to identify the...

Full description

Saved in:

Bibliographic Details
Published in:	Hepatology (Baltimore, Md.) Vol. 65; no. 2; pp. 439 - 450
Main Authors:	Lawitz, Eric, Poordad, Fred, Gutierrez, Julio A., Wells, Jennifer T., Landaverde, Carmen E., Evans, Barbara, Howe, Anita, Huang, Hsueh‐Cheng, Li, Jerry Jing, Hwang, Peggy, Dutko, Frank J., Robertson, Michael, Wahl, Janice, Barr, Eliav, Haber, Barbara
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01-02-2017
Subjects:	Adult Aged Amides Antiviral agents Antiviral drugs Benzofurans - administration & dosage Carbamates Chronic infection Cirrhosis Confidence Intervals Cyclopropanes Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies Genotypes Hepacivirus - drug effects Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C - diagnosis Hepatitis C - drug therapy Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - drug therapy Hepatology Humans Imidazoles - administration & dosage Infections Liver cirrhosis Male Middle Aged Prospective Studies Pruritus Quinoxalines - administration & dosage Ribavirin Ribonucleic acid RNA RNA, Viral - analysis Sulfonamides Time Factors Treatment Outcome Viral Load - drug effects
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!